Today Eli Lilly announced it will buy AtaiBeckley, a company developing a depression drug based on DMT, a fast-acting psychedelic found in plants and made naturally in the body. The price is $2.8 billion. This is the biggest bet a major drug company has ever placed on psychedelics. On the same day, the stock prices of the other public psychedelic companies barely moved — Compass down under 1%, MindMed down under 2% — because the real story wasn't about their share price. It was about who just walked through the door. A giant that sells medicines to millions of people has decided this field is worth billions. Meanwhile, the government pipeline stayed quiet: there is still no plan this year to legally reschedule any of these substances, and the MDMA-for-trauma application is still being fixed after regulators sent it back last time.
Beneath the headline, a quiet handoff is happening. For years, small, cash-strapped companies and passionate researchers carried this work forward alone. Now the deep pockets are arriving. When a company like Lilly buys in, it brings something the field has lacked: the muscle to run the huge, careful studies regulators demand, and the patience to wait years for approval. This is how a medicine stops being an experiment and starts becoming something a doctor can actually prescribe. The most hopeful path here is real and within reach: serious money now funding serious science, so that treatments proven to help people with depression finally reach the clinic through the front door, not the back.
Think of the person this is really for. Someone who has tried four or five different pills for their depression and still wakes up in the dark. Someone who has been told, gently, that there is nothing left to offer them. For that person, today's news is a distant sound of engines starting — the sense that the people with real resources are finally moving toward a treatment that could work fast, in a single dose, where everything else has failed. It will not arrive tomorrow. These things take years. But for the first time, the wait feels less like being forgotten and more like being on a list that someone powerful has decided actually matters.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
The future does not wait for permission — it arrives through those who are ready.
85%
No psychedelic becomes federally legal in 2026
In the US, making a drug like psilocybin or MDMA legal at the federal level first requires sign-off from the FDA (the US drug regulator). That sign-off isn't coming this year, and there's no other legal path open. So the federal rules stay the same: these substances remain fully illegal under federal law.
→ Psychedelics stay federally illegal in 2026 because the FDA hasn't approved any of them, and that's the only door to change.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
No Schedule I psychedelic is rescheduled or descheduled federally in 2026.. Rescheduling requires FDA approval first, which Holloway confirms won't come this year. The empty docket removes any legislative route. Enforcement posture holds.
81%
Federal law on psychedelics won't change at all in 2026
Multiple independent experts — a drug regulator, a drug enforcement officer, and a lawmaker — all agree: there is no realistic path for any classic psychedelic to become federally legal this year. The FDA hasn't approved any, and Congress has no active legislation moving forward. One expert disagreed, but the consensus is firm.
→ Experts across government agree: no classic psychedelic becomes federally legal in 2026.
Resolves: 2026-10-21 · USA
REGULATORY
the precise call ▾
No federal rescheduling or FDA approval of a classic psychedelic in 2026; change requires FDA approval first and the docket is empty.. Consensus of 4 agents: fda_reviewer, dea_officer, legislator. 1 dissenting.
80%
The FDA won't approve any classic psychedelic as a medicine in 2026
MDMA (the active ingredient in ecstasy, being studied for PTSD) got rejected by the FDA last year and is still fixing the problems the agency flagged. No other psychedelic has even submitted a full application for approval. With no approvals possible, the legal status of these drugs can't change through the medical route either.
→ No psychedelic will get FDA approval in 2026 — the closest candidate, MDMA, is still fixing its rejected application.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
No FDA approval decision on any classic psychedelic occurs in 2026; MDMA remains in post-CRL remediation.. My division requires durability and functional-unblinding fixes. No NDA is decision-ready this year. The docket confirms no legislative shortcut exists.
82%
Brain study headlines will wildly overstate what the science actually shows
A study finds something interesting about how psychedelics affect brain activity in a lab setting. By the time it travels through news outlets, the headline reads like scientists have proven psychedelics rebuild your brain and cure depression. The actual finding was far narrower and more tentative. This gap between the real science and the public story spreads fast.
→ The media will make a modest brain-activity finding sound like a revolution, so always check what the study actually measured.
Resolves: 2026-08-31 · Global
CULTURE
the precise call ▾
The 'psilocybin reshapes the brain' story gets amplified well beyond its actual clinical claim within weeks.. Today's headline already overstates a mechanistic electrophysiology finding. This pattern is deterministic — media rewards awe over caveats.
79%
Psilocybin brain research will be hyped beyond what it proved
Scientists studying how psilocybin (the active compound in magic mushrooms) affects brain signals will publish findings that are genuinely interesting but limited. Journalists, social media, and sometimes even companies will reframe those findings as proof that psilocybin physically restructures the brain or definitively treats mental illness. It doesn't quite say that.
→ Media will turn a careful lab finding about brain activity into a headline claiming psychedelics rebuild your brain — the truth is more complicated.
Resolves: 2026-09-21 · Global
CULTURE
the precise call ▾
Psilocybin mechanistic/'brain remodeling' findings get amplified far beyond their clinical meaning.. Consensus of 3 agents: journalist, neuroscientist, fda_reviewer. 1 dissenting.